FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Designates Avelumab Breakthrough Therapy

[ Price : $8.95]

FDA says that Merck and Pfizers avelumab is a breakthrough therapy for patients with metastatic Merkel cell carcinoma.

3 Topics at PDUFA 6 Reauthorization Meeting

[ Price : $8.95]

FDA makes presentations biomarkers, the benefit/risk framework, and patient-reported outcomes at a PDUFA 6 reauthorization stakeho...

Final Guidance on LDT Oversight Due Next Year: Shuren

[ Price : $8.95]

CDRH director Jeffrey Shuren says his Center intends to finalize early next year its guidance on aFramework for Regulatory Oversig...

AngioDynamics Resolves Warning Letter on NanoKnife System

[ Price : $8.95]

FDA issues AngioDynamics a close-out letter effectively resolving promotional issues raised in a 2011 Warning Letter involving its...

FDA Posts Approved PMAs

[ Price : $8.95]

Federal Register Notice: FDA publishes a list of approved PMAs and their safety and effectiveness summaries.

WLF Cries Foul on CDC Opioid Prescribing Guideline

[ Price : $8.95]

The Washington Legal Foundation calls on the Centers for Disease Control and Prevention (CDC) to withdraw its Draft Guideline for ...

FDA Clears Hikma Plant Corrective Actions

[ Price : $8.95]

FDA says Hikma Pharmaceuticals has sufficiently corrected GMP violations at its Portuguese drug manufacturing facility.

FDA Accepts Sandoz Neulasta Biosimilar Application

[ Price : $8.95]

FDA accepts Sandoz regulatory submission for a biosimilar of Amgens Neulasta.

FDA Approves Medtronic MyCareLink Monitor

[ Price : $8.95]

FDA approves Medtronics MyCareLink remote pacemaker monitoring system.

FDA Issues Staff Social Media Policy

[ Price : $8.95]

FDA issues a policy on staff use of social media on behalf of the agency and its mission.